Halozyme Therapeutics Inc. Insider Trading

HALO

Last 12 months

Insiders sold $48.1M and bought nothing on the open market.

96% of the selling was scheduled in advance under 10b5-1 plans. SVP, Chief Operating Officer Cortney Caudill sold $1.96M on Mar 10, 80% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2020.

Net open-market

−$48.1M

0 buys · 23 sales

Under a 10b5-1 plan

96%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Mar 2020

Mar 19, 2020

Get an email when HALO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 6 – 8	Helen Torley President and CEO	Sold10b5-1 plan 12 parts	60,000	$110.18 average	$6.61M	7.2%	Form 4
Oct 1	Matthew L. Posard Director	Sold10b5-1 plan 4 parts	5,230	$108.54 average	568K	8.9%	Form 4
Sep 16	Matthew L. Posard Director	Sold10b5-1 plan 4 parts	18,996	$107.74 average	$2.05M	24%	Form 4
Sep 9 – 11	Helen Torley President and CEO	Sold10b5-1 plan 7 parts	60,000	$107.28 average	$6.44M	7.2%	Form 4
Aug 17 – 19	Helen Torley President and CEO	Sold10b5-1 plan 11 parts	60,000	$104.59 average	$6.28M	7.2%	Form 4
Aug 10	Bernadette Connaughton Director	Sold10b5-1 plan	1,626	$102.80	167K	3.9%	Form 4
Jul 8	Helen Torley President and CEO	Sold10b5-1 plan 2 parts	1,923	$79.77 average	153K	0.2%	Form 4
Jul 1	Bernadette Connaughton Director	Sold10b5-1 plan 2 parts	1,625	$76.71 average	125K	3.7%	Form 4
Jun 29	Mahesh Krishnan Director	Sold10b5-1 plan	7,304	$75.00	548K	34%	Form 4
Jun 1 – 3	Helen Torley President and CEO	Sold10b5-1 plan 9 parts	50,000	$67.40 average	$3.37M	6.1%	Form 4
Jun 1	Bernadette Connaughton Director	Sold10b5-1 plan	1,625	$66.21	108K	3.6%	Form 4
May 11 – 13	Helen Torley President and CEO	Sold10b5-1 plan 12 parts	50,000	$68.68 average	$3.43M	6.1%	Form 4
May 1	Bernadette Connaughton Director	Sold10b5-1 plan	1,625	$63.48	103K	4.1%	Form 4
Apr 6	Helen Torley President and CEO	Sold10b5-1 plan 2 parts	10,000	$63.50 average	635K	1.3%	Form 4
Apr 1 – 2	Helen Torley President and CEO	Sold10b5-1 plan 4 parts	40,000	$64.81 average	$2.59M	5.0%	Form 4
Mar 9 – 10	Cortney Caudill SVP, Chief Operating Officer	SoldNo plan 3 parts	28,857	$67.75 average	$1.96M	80%	Form 4
Mar 2 – 4	Helen Torley President and CEO	Sold10b5-1 plan 7 parts	50,000	$69.52 average	$3.48M	6.1%	Form 4
Feb 3 – 5	Helen Torley President and CEO	Sold10b5-1 plan 7 parts	50,000	$77.07 average	$3.85M	6.6%	Form 4
Jan 5	Bernadette Connaughton Director	Sold10b5-1 plan	2,000	$70.25	141K	4.7%	Form 4
Dec 1, 2025	Bernadette Connaughton Director	Sold10b5-1 plan	829	$71.60	59K	1.9%	Form 4
Dec 1, 2025	Helen Torley President and CEO	Sold10b5-1 plan 4 parts	16,569	$68.92 average	$1.14M	2.3%	Form 4
Nov 10, 2025 – Nov 12, 2025	Helen Torley President and CEO	Sold10b5-1 plan 8 parts	60,000	$69.46 average	$4.17M	7.6%	Form 4
Nov 10, 2025	Bernadette Connaughton Director	Sold10b5-1 plan	2,000	$68.48	137K	4.4%	Form 4
Nov 1, 2025	Cortney Caudill SVP, Chief Operating Officer	SoldNo plan	4,263	$65.19	278K	25%	Form 4
Oct 1, 2025 – Oct 3, 2025	Helen Torley President and CEO	Sold10b5-1 plan 11 parts	60,000	$71.86 average	$4.31M	7.6%	Form 4
Oct 1, 2025	Bernadette Connaughton Director	Sold10b5-1 plan 2 parts	2,000	$75.24 average	150K	4.3%	Form 4
Sep 22, 2025	Nicole Labrosse SVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	2,227	$77.95 average	174K	9.2%	Form 4
Sep 10, 2025	Nicole Labrosse SVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	20,000	$75.71 average	$1.51M	45%	Form 4
Sep 2, 2025 – Sep 4, 2025	Helen Torley President and CEO	Sold10b5-1 plan 8 parts	60,000	$74.08 average	$4.44M	7.6%	Form 4
Sep 2, 2025	Bernadette Connaughton Director	Sold10b5-1 plan 3 parts	4,000	$73.69 average	295K	7.9%	Form 4
Aug 11, 2025 – Aug 13, 2025	Helen Torley President and CEO	Sold10b5-1 plan 6 parts	60,000	$63.62 average	$3.82M	7.6%	Form 4
Jul 8, 2025 – Jul 10, 2025	Helen Torley President and CEO	Sold10b5-1 plan 6 parts	60,000	$56.46 average	$3.39M	7.6%	Form 4
Jun 20, 2025 – Jun 24, 2025	Helen Torley President and CEO	Sold10b5-1 plan 4 parts	60,000	$53.09 average	$3.19M	7.6%	Form 4
Apr 28, 2025	Jeffrey William Henderson Director	Sold10b5-1 plan 2 parts	4,497	$60.37 average	271K	14%	Form 4
Apr 1, 2025	Jeffrey William Henderson Director	Sold10b5-1 plan	503	$64.05	32K	1.5%	Form 4
Mar 3, 2025	Jeffrey William Henderson Director	Sold10b5-1 plan 2 parts	5,000	$58.69 average	293K	13%	Form 4
Feb 25, 2025 – Feb 27, 2025	Michael J. Labarre SVP, Chief Technical Officer	Sold10b5-1 plan 6 parts	21,697	$58.10 average	$1.26M	11%	Form 4
Feb 3, 2025	Jeffrey William Henderson Director	Sold10b5-1 plan 2 parts	5,000	$56.31 average	282K	11%	Form 4
Jan 6, 2025	Jeffrey William Henderson Director	Sold10b5-1 plan	10,000	$50.01	500K	19%	Form 4

Oct 6 – 810b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $110.18
$6.61M
7.2% of stake
Oct 110b5-1 plan
Matthew L. Posard
Director · sold 5,230 at avg $108.54
568K
8.9% of stake
Sep 1610b5-1 plan
Matthew L. Posard
Director · sold 18,996 at avg $107.74
$2.05M
24% of stake
Sep 9 – 1110b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $107.28
$6.44M
7.2% of stake
Aug 17 – 1910b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $104.59
$6.28M
7.2% of stake
Aug 1010b5-1 plan
Bernadette Connaughton
Director · sold 1,626 at $102.80
167K
3.9% of stake
Jul 810b5-1 plan
Helen Torley
President and CEO · sold 1,923 at avg $79.77
153K
0.2% of stake
Jul 110b5-1 plan
Bernadette Connaughton
Director · sold 1,625 at avg $76.71
125K
3.7% of stake
Jun 2910b5-1 plan
Mahesh Krishnan
Director · sold 7,304 at $75.00
548K
34% of stake
Jun 1 – 310b5-1 plan
Helen Torley
President and CEO · sold 50,000 at avg $67.40
$3.37M
6.1% of stake
Jun 110b5-1 plan
Bernadette Connaughton
Director · sold 1,625 at $66.21
108K
3.6% of stake
May 11 – 1310b5-1 plan
Helen Torley
President and CEO · sold 50,000 at avg $68.68
$3.43M
6.1% of stake
May 110b5-1 plan
Bernadette Connaughton
Director · sold 1,625 at $63.48
103K
4.1% of stake
Apr 610b5-1 plan
Helen Torley
President and CEO · sold 10,000 at avg $63.50
635K
1.3% of stake
Apr 1 – 210b5-1 plan
Helen Torley
President and CEO · sold 40,000 at avg $64.81
$2.59M
5.0% of stake
Mar 9 – 10No plan
Cortney Caudill
SVP, Chief Operating Officer · sold 28,857 at avg $67.75
$1.96M
80% of stake
Mar 2 – 410b5-1 plan
Helen Torley
President and CEO · sold 50,000 at avg $69.52
$3.48M
6.1% of stake
Feb 3 – 510b5-1 plan
Helen Torley
President and CEO · sold 50,000 at avg $77.07
$3.85M
6.6% of stake
Jan 510b5-1 plan
Bernadette Connaughton
Director · sold 2,000 at $70.25
141K
4.7% of stake
Dec 1, 202510b5-1 plan
Bernadette Connaughton
Director · sold 829 at $71.60
59K
1.9% of stake
Dec 1, 202510b5-1 plan
Helen Torley
President and CEO · sold 16,569 at avg $68.92
$1.14M
2.3% of stake
Nov 10, 2025 – Nov 12, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $69.46
$4.17M
7.6% of stake
Nov 10, 202510b5-1 plan
Bernadette Connaughton
Director · sold 2,000 at $68.48
137K
4.4% of stake
Nov 1, 2025No plan
Cortney Caudill
SVP, Chief Operating Officer · sold 4,263 at $65.19
278K
25% of stake
Oct 1, 2025 – Oct 3, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $71.86
$4.31M
7.6% of stake
Oct 1, 202510b5-1 plan
Bernadette Connaughton
Director · sold 2,000 at avg $75.24
150K
4.3% of stake
Sep 22, 202510b5-1 plan
Nicole Labrosse
SVP, Chief Financial Officer · sold 2,227 at avg $77.95
174K
9.2% of stake
Sep 10, 202510b5-1 plan
Nicole Labrosse
SVP, Chief Financial Officer · sold 20,000 at avg $75.71
$1.51M
45% of stake
Sep 2, 2025 – Sep 4, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $74.08
$4.44M
7.6% of stake
Sep 2, 202510b5-1 plan
Bernadette Connaughton
Director · sold 4,000 at avg $73.69
295K
7.9% of stake
Aug 11, 2025 – Aug 13, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $63.62
$3.82M
7.6% of stake
Jul 8, 2025 – Jul 10, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $56.46
$3.39M
7.6% of stake
Jun 20, 2025 – Jun 24, 202510b5-1 plan
Helen Torley
President and CEO · sold 60,000 at avg $53.09
$3.19M
7.6% of stake
Apr 28, 202510b5-1 plan
Jeffrey William Henderson
Director · sold 4,497 at avg $60.37
271K
14% of stake
Apr 1, 202510b5-1 plan
Jeffrey William Henderson
Director · sold 503 at $64.05
32K
1.5% of stake
Mar 3, 202510b5-1 plan
Jeffrey William Henderson
Director · sold 5,000 at avg $58.69
293K
13% of stake
Feb 25, 2025 – Feb 27, 202510b5-1 plan
Michael J. Labarre
SVP, Chief Technical Officer · sold 21,697 at avg $58.10
$1.26M
11% of stake
Feb 3, 202510b5-1 plan
Jeffrey William Henderson
Director · sold 5,000 at avg $56.31
282K
11% of stake
Jan 6, 202510b5-1 plan
Jeffrey William Henderson
Director · sold 10,000 at $50.01
500K
19% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch HALO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with HALO

CompareIntrinsic value

TECHBio-Techne Corporation

$72.73+0.10%52

MRNAModerna, Inc.

$258.31+13.08%20

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

EXELExelixis Inc.

$72.75+0.61%97

RGENRepligen Corporation

$178.20-0.04%35

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

ADMAAdma Biologics Inc.

$10.48-5.67%82

KRYSKrystal Biotech Inc.

$310.84+1.90%44

Held by ETFs

HALO is in 174 US ETFs. The largest of them, with HALO's weight in each:

Spot a number that looks wrong? Check it in HALO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HALO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.